Inotek Pharmaceuticals Corp ITEK shares are trading lower by $4.27 at $1.83 in Tuesday's session. The catalyst for the 70 percent decline is that its Phase 3 Trial of Trabodenoson for the treatment for Glaucoma did not meet it primary endpoint in its first Phase 3 trial.
So far, its sharply lower open stands as the high for the day at $2.20. From there, it has continued to make new lows for the session with the current one standing at $1.75. At this time, it has not been able to distance itself from that depressed level.
That low far exceeds its former all-time low that was made in April 2015 at $4.68. Today's price action is taking place on much higher average volume as 7.2 million shares have already traded compared to its 20-day average of only 683,000.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.